| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Charles P Semba | |
| Thomas R Gadek | |||
| P2860 | cites work | The immunological synapse: a molecular machine controlling T cell activation | Q28139151 |
| Prevalence of dry eye syndrome among US women | Q28196875 | ||
| Heterogeneous mutations in the beta subunit common to the LFA-1, Mac-1, and p150,95 glycoproteins cause leukocyte adhesion deficiency | Q28301257 | ||
| Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A | Q28316169 | ||
| Ophthalmologist perceptions regarding treatment of moderate to severe dry eye: results of a physician survey. | Q33623447 | ||
| Prevalence of dry eye disease among US men: estimates from the Physicians' Health Studies | Q33720070 | ||
| Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease | Q33869200 | ||
| The use of vital dyes in corneal disease | Q34025732 | ||
| The pharmacologic assessment of a novel lymphocyte function-associated antigen-1 antagonist (SAR 1118) for the treatment of keratoconjunctivitis sicca in dogs | Q34165372 | ||
| Small-molecule inhibitors of protein-protein interactions: progressing toward the reality | Q34263719 | ||
| Emerging treatment options for meibomian gland dysfunction | Q34371781 | ||
| Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study | Q34493904 | ||
| Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin (STZ) model of diabetic retinopathy (DR) | Q34735196 | ||
| Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1) | Q68202545 | ||
| Purification and structural characterization of LFA-1, a lymphocyte function-associated antigen, and Mac-1, a related macrophage differentiation antigen associated with the type three complement receptor | Q71439783 | ||
| Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes | Q73180482 | ||
| Reliability and validity of the Ocular Surface Disease Index | Q73801624 | ||
| Performance and repeatability of the NEI-VFQ-25 in patients with dry eye | Q74492517 | ||
| Development and validation of a short global dry eye symptom index | Q79657699 | ||
| The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007) | Q80347907 | ||
| Methodologies to diagnose and monitor dry eye disease: report of the Diagnostic Methodology Subcommittee of the International Dry Eye WorkShop (2007) | Q80347912 | ||
| Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007) | Q80347919 | ||
| Tear meniscus measurement by spectral optical coherence tomography | Q83335809 | ||
| A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye | Q83435570 | ||
| Immune response in the conjunctival epithelium of patients with dry eye | Q84589672 | ||
| Evaluation of lipid layer thickness measurement of the tear film as a diagnostic tool for Meibomian gland dysfunction | Q86478230 | ||
| Neurostimulation of the lacrimal nerve for enhanced tear production | Q35085293 | ||
| T-cell integrins: more than just sticking points | Q35576652 | ||
| Impact of dry eye syndrome on vision-related quality of life | Q35741609 | ||
| Tear cytokine profiles in dysfunctional tear syndrome. | Q36637791 | ||
| Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study | Q36877000 | ||
| The role of the integrin LFA-1 in T-lymphocyte migration | Q36877329 | ||
| Dry eye disease: an immune-mediated ocular surface disorder | Q36916372 | ||
| The challenge of dry eye diagnosis | Q37233339 | ||
| Etiology, prevalence, and treatment of dry eye disease | Q37288773 | ||
| Receptor signaling clusters in the immune synapse | Q37725089 | ||
| The international workshop on meibomian gland dysfunction: executive summary | Q37859542 | ||
| The lymphocyte function-associated LFA-1, CD2, and LFA-3 molecules: cell adhesion receptors of the immune system | Q39595455 | ||
| Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye. | Q39730888 | ||
| Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. | Q40948258 | ||
| Aspects of VLA-4 and LFA-1 regulation that may contribute to rolling and firm adhesion. | Q42051797 | ||
| Generation of an LFA-1 antagonist by the transfer of the ICAM-1 immunoregulatory epitope to a small molecule | Q42162451 | ||
| Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study | Q42708147 | ||
| Competition between intercellular adhesion molecule-1 and a small-molecule antagonist for a common binding site on the alphal subunit of lymphocyte function-associated antigen-1. | Q43043542 | ||
| The value of tear osmolarity as a metric in evaluating the response to dry eye therapy in the clinic and in clinical trials | Q44062511 | ||
| Safety and pharmacokinetics of a novel lymphocyte function-associated antigen-1 antagonist ophthalmic solution (SAR 1118) in healthy adults | Q44243837 | ||
| N-Benzoyl amino acids as LFA-1/ICAM inhibitors 1: amino acid structure-activity relationship | Q44366532 | ||
| Small molecule integrin antagonists that bind to the beta2 subunit I-like domain and activate signals in one direction and block them in the other | Q44589706 | ||
| ICAM-1 expression predisposes ocular tissues to immune-based inflammation in dry eye patients and Sjögrens syndrome-like MRL/lpr mice | Q44809776 | ||
| N-Benzoyl amino acids as ICAM/LFA-1 inhibitors. Part 2: structure-activity relationship of the benzoyl moiety | Q44841587 | ||
| Topical loteprednol pretreatment reduces cyclosporine stinging in chronic dry eye disease | Q44961509 | ||
| The lack of association between signs and symptoms in patients with dry eye disease | Q45122466 | ||
| Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye. | Q45122469 | ||
| Correlation between corneal sensitivity, subjective dry eye symptoms and corneal staining in Sjögren's syndrome. | Q45254744 | ||
| Conjunctival T-cell subpopulations in Sjögren's and non-Sjögren's patients with dry eye. | Q45950875 | ||
| The role of apoptosis in the pathogenesis of canine keratoconjunctivitis sicca: the effect of topical Cyclosporin A therapy | Q46658333 | ||
| Correlation of Tear Film Osmolarity and 2 Different MMP-9 Tests With Common Dry Eye Tests in a Cohort of Non-Dry Eye Patients. | Q50279252 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | eye disease | Q3041498 |
| lifitegrast | Q23044263 | ||
| P304 | page(s) | 1083-94 | |
| P577 | publication date | 2016-01-01 | |
| P1433 | published in | Clinical Ophthalmology | Q5133782 |
| P1476 | title | Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease | |
| P478 | volume | 10 |
| Q100558870 | A novel serine protease inhibitor as potential treatment for dry eye syndrome and ocular inflammation |
| Q38369119 | Anti-inflammatory effect of hydroxyproline-GQDGLAGPK in desiccation stress-induced experimental dry eye mouse |
| Q89539996 | Aqueous deficiency is a contributor to evaporation-related dry eye disease |
| Q48095233 | Current Anti-Integrin Therapy for Ocular Disease |
| Q57378488 | Current and emerging therapy of dry eye disease. Part A: pharmacological modalities |
| Q47639135 | Dry eye syndrome: developments and lifitegrast in perspective |
| Q64244837 | Effect of topical 0.05% cyclosporine A on the tear protein lacritin in a rat model of dry eye |
| Q51836466 | Effects of Aging in Dry Eye. |
| Q60054513 | Intramembrane ionic protein-lipid interaction regulates integrin structure and function |
| Q39069560 | Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease |
| Q33739879 | Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy |
| Q37591609 | Lifitegrast: A novel drug for treatment of dry eye disease |
| Q91739477 | Meibomian gland dysfunction, dropout and distress: emerging therapies |
| Q52558847 | Phosphosulindac is efficacious in an improved concanavalin A-based rabbit model of chronic dry eye disease. |
| Q58694745 | Safety and efficacy of lifitegrast 5% ophthalmic solution in contact lens discomfort |
| Q33364715 | Solving the puzzle: What is behind our forefathers' anti-inflammatory remedies? |
| Q93108648 | The Psoriasis Therapeutic Potential of a Novel Short Laminin Peptide C16 |
| Q50110517 | Therapeutic inhibitors for the treatment of dry eye syndrome. |
Search more.